2Johnson B J, Estrada, Shen Z, et al. Differential gene expression in response to adjunctive recombinant human interleukin-2 immunotherapy in multidrug- resistant tuberculosis patients[J]. Infect Immun, 1998, 66(6): 2426.
3Johnson B J, Bekker L G, Rickrnan R, et al. rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo [ J ]. Tuber Lung Dis,1997, 78(3-4): 195.
6Uhlin M, Andersson J, Zumla A, et al. Adiunct im- munotherapies for tuberculosis [ J ]. J Infect Dis, 2012. [Epub ahead of print].
7Mercedes G J. Immunity to TB and targets for immunothera- py[J]. Immunotherapy, 2012, 4(2): 187.
8Johnson B J, Bekker L G, Rickman R, et al. rhlL-2 adiunc- tive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo[J]. Tubercle and Lung DiseAse. 1997. 78(3-4), 195.
9Dheda K, Schwmlder S K, Zhu B D, et al. The immunology of tuberculoisis: From bench to beside[J]. Respirogy, 2010, 15 : 433.
10Barnes P F. Immunotherapy for tuberculosis: wave of the fu- ture or tilting at windmills? [ J ]. Am J Resp Crit Care, 2003, 168: 142.
